Up And Coming Drug Stocks

Comment

Comment by Stocks To Buy on February 3, 2012 at 3:20pm

GALE - testing 1 again

Comment by Stocks To Buy on November 13, 2011 at 6:26am

3 Up and Coming Drugs stocks to Buy on pullbacks:

Pharmasset, Inc. (VRUS)
Inhibitex, Inc. (INHX)
Aastrom Biosciences, Inc. (ASTM)

Comment by Stocks To Buy on March 17, 2011 at 8:23am

Cardiovascular Systems Inc. (CSII) - Cardiovascular Systems Receives FDA 510(k) Marketing Clearance for Stealth 360°™ Orbital PAD System

http://finance.yahoo.com/news/Cardiovascular-Systems-bw-3445936111....

Comment by Stocks To Buy on October 20, 2010 at 10:45am

EnteroMedics, Inc. (ETRM) - EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies

http://finance.yahoo.com/news/EnteroMedics-Announces-iw-1429355963....

Comment by Gerry Gallagher on August 5, 2010 at 5:54pm

PLBI is now listed as a STRONG BUY on the barchart website so have a look and pass on the good news: http://www.barchart.com/quotes/stocks/PLBI

Comment by Stocks To Buy on June 1, 2010 at 2:41pm

Questcor Pharmaceuticals, Inc. (QCOR) - FDA Decision coming on or before June 11, 2010 - Spasms in infants

Comment by ArifNaim on May 31, 2010 at 4:12pm

AstraZeneca PLC waiting for Motavizumab (BLA) , 06/02/2010

Sales potential of $1.3 billion a year by 2014, according to analysts

Comment by Terry H on December 13, 2009 at 9:24pm

SNSS Reuters report:Cowen & Co analyst Craig Gordon attributed the gains on Thursday and Friday to investors speculating about a possible partnership on the drug and the positive data.
"If you ask me for percentages, I think 60 percent to 70 percent of the spike is on the chances of a partnership and 30 percent to 40 percent is from the data," Gordon said.
Sunesis Pharmaceuticals' (SNSS:$1.72,00$0.33,0023.74%) Chief Financial Officer Eric Bjerkholt told Reuters that the company was already in talks for a partnership.
We're exploring alternatives for funding for that (late-stage) trial, and partnerships is one of the alternatives that are being explored, Bjerkholt said.
"And then, yes, the last alternative might be to sell the company," he added. Bjerkholt said he would not be able to comment on which option the company would prefer until the terms on the funding alternatives were available. Sunesis, which has $3.9 million in cash and marketable securities as of Sept 30, is already in talks with possible partners on the drug, or buyers.
The CFO denied commenting if the deal talks were with buyers or with potential partners.
"One of the reasons we are attracted to discussing with partners is that there is a broader development plan than we could possible fund on our own," Bjerkholt said.
Cowen & Co's Gordon sees an upfront payment of between $50 million to $70 million on the drug, but does not rule out a possible acquisition of the company.
"So with a partnership we can have a joint development plan that could hopefully include other indications," he added.
On Monday, Sunesis said the Phase Ib/II study of Voreloxin showed a preliminary median overall survival of 7.8 months in patients suffering from relapsed or refractory acute myeloid leukemia. The biopharmaceutical company also determined an optimum dose in a mid-stage study.
Sunesis shares were up 23 percent at $1.71 Friday afternoon on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Anil D'Silva)

Comment by Stocks To Buy on December 13, 2009 at 9:02pm

SNSS, CYCC - big movers last week.....do your research

Comment by Stocks To Buy on November 3, 2009 at 5:06pm

Xenoport (XNPT) Next Biotech stock to watch - November 9, 2009 - FDA decision

http://www.thestreet.com/story/10619916/1/biotech-calendar-key-date...

• ‹ Previous
• 1
• 2
• 3
• Next ›
• Page